TY - JOUR
T1 - Sex-Related Differences in Patients With Inflammatory Bowel Disease
T2 - Results of 2 Prospective Cohort Studies
AU - Severs, Mirjam
AU - Spekhorst, Lieke M
AU - Mangen, Marie-Josée J
AU - Dijkstra, Gerard
AU - Löwenberg, Mark
AU - Hoentjen, Frank
AU - van der Meulen-de Jong, Andrea E
AU - Pierik, Marieke
AU - Ponsioen, Cyriel Y
AU - Bouma, Gerd
AU - van der Woude, Janneke C
AU - van der Valk, Mirthe E
AU - Romberg-Camps, Marielle J L
AU - Clemens, Cees H M
AU - van de Meeberg, Paul
AU - Mahmmod, Nofel
AU - Jansen, Jeroen
AU - Jharap, Bindia
AU - Weersma, Rinse K
AU - Oldenburg, Bas
AU - Festen, Eleonora A M
AU - Fidder, Herma H
N1 - Funding Information:
Supported by the Parelsnoer Institute (PSI), the COIN study group, and the Initiative on Crohn’s and Colitis. This nationwide Parelsnoer Institute project is part of and funded by the Netherlands Federation of University Medical Centers and has received initial funding from the Dutch Government (2007–2011). The Parelsnoer Institute currently facilitates the uniform nationwide collection of information on and biomaterials of 13 other diseases. RK Weersma is supported by a VIDI grant (016.136.308) from the Netherlands Organization for Scientific Research (NWO). EAM Festen is supported by a Career Development grant of the Dutch Digestive Foundation (CDG 14-04).
Funding Information:
Potential conflicts of interest: HHF has acted as a consultant for AbbVie. GD: participated on an advisory board of Mundipharma. AEvdMdJ has acted as consultant for AbbVie, MSD, Ferring and Falk and received payments for lectures from AbbVie and MSD. FH has served on advisory boards of MSD, Takeda, Celltrion, Teva, Sandoz, and Dr. Falk and served as a consultant for Celgene. CYP has acted as a consultant for AbbVie and received payments for lectures from Ferring and MSD. CJvdW has acted as a consultant for AbbVie, Ferring, Shire, and MSD and received payment for lectures from AbbVie, Falk Pharma, and MSD. PvdM received payments for lectures for Falk. JMJ has acted as a consultant for AbVvie, MSD, Ferring, and Falk and received payments for lectures for AbbVie and MSD. RKW reports unrestricted research grants from Ferring, Tramedico and Takeda Pharmaceutical Companies and personal fees during the conduct of the study from Abbott outside the submitted work. BO has acted as a consultant for AbbVie, Takeda, and MSD and received payment for lectures from Ferring, MSD, and AbbVie. * These authors contributed equally to this work. # These authors contributed equally to this work.
Publisher Copyright:
© 2018 Crohn's & Colitis Foundation. Published by Oxford University Press. All rights reserved.
PY - 2018/6
Y1 - 2018/6
N2 - Background The understanding of gender differences in inflammatory bowel disease (IBD) patients is an important step towards tailored treatment for the individual patient. The aim of this study was to compare disease phenotype, clinical manifestations, disease activity, and healthcare utilization between men and women with Crohn's disease (CD) and ulcerative colitis (UC). Methods Two multicenter observational cohort studies with a prospective design were used to explore the differences between men and women regarding demographic and phenotypic characteristics and healthcare utilization. Detailed data on IBD-phenotype was mainly available from the Dutch IBD Biobank, while the COIN cohort provided healthcare utilization data. Results In the Dutch IBD Biobank study, 2118 CD patients and 1269 UC patients were analyzed. Female CD patients were more often current smokers, and male UC patients were more often previous smokers. Early onset CD (<16 years) was more frequently encountered in males than in females (20% versus 12%, P < 0.01). Male CD patients were more often diagnosed with ileal disease (28% versus 20%, P < 0.01) and underwent more often small bowel and ileocecal resection. Extraintestinal manifestations (EIMs) were more often encountered in female IBD patients. In the COIN study, 1139 CD patients and 1213 UC patients were analyzed. Male CD patients used prednisone more often and suffered more often from osteopenia. IBD-specific healthcare costs did not differ between male and female IBD patients. Conclusions Sex differences in patients with IBD include age of onset, disease location, and EIM prevalence. No large differences in therapeutic management of IBD were observed between men and women with IBD.
AB - Background The understanding of gender differences in inflammatory bowel disease (IBD) patients is an important step towards tailored treatment for the individual patient. The aim of this study was to compare disease phenotype, clinical manifestations, disease activity, and healthcare utilization between men and women with Crohn's disease (CD) and ulcerative colitis (UC). Methods Two multicenter observational cohort studies with a prospective design were used to explore the differences between men and women regarding demographic and phenotypic characteristics and healthcare utilization. Detailed data on IBD-phenotype was mainly available from the Dutch IBD Biobank, while the COIN cohort provided healthcare utilization data. Results In the Dutch IBD Biobank study, 2118 CD patients and 1269 UC patients were analyzed. Female CD patients were more often current smokers, and male UC patients were more often previous smokers. Early onset CD (<16 years) was more frequently encountered in males than in females (20% versus 12%, P < 0.01). Male CD patients were more often diagnosed with ileal disease (28% versus 20%, P < 0.01) and underwent more often small bowel and ileocecal resection. Extraintestinal manifestations (EIMs) were more often encountered in female IBD patients. In the COIN study, 1139 CD patients and 1213 UC patients were analyzed. Male CD patients used prednisone more often and suffered more often from osteopenia. IBD-specific healthcare costs did not differ between male and female IBD patients. Conclusions Sex differences in patients with IBD include age of onset, disease location, and EIM prevalence. No large differences in therapeutic management of IBD were observed between men and women with IBD.
KW - Journal Article
KW - gender
KW - sex
KW - Crohn's disease
KW - ulcerative colitis
KW - inflammatory bowel disease
KW - Colitis, Ulcerative/epidemiology
KW - Severity of Illness Index
KW - Crohn Disease/epidemiology
KW - Prevalence
KW - Prospective Studies
KW - Humans
KW - Middle Aged
KW - Risk Factors
KW - Male
KW - Sex Factors
KW - Adult
KW - Female
KW - Netherlands/epidemiology
UR - https://www.scopus.com/pages/publications/85047537297
U2 - 10.1093/ibd/izy004
DO - 10.1093/ibd/izy004
M3 - Article
C2 - 29688413
SN - 1078-0998
VL - 24
SP - 1298
EP - 1306
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 6
ER -